Burlington-based Dyax Corp. said Thursday that it is partnering with a Colombian company that will develop and commercialize its hereditary angiodema treatment in such Latin American countries as Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.

The strategic partnership is with Novellus Biopharma AG of Bogota. Dyax’s press release did not include financial details of the partnership agreement.